| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| SHALLCROSS STEVEN A | CEO and CFO, Director | C/O THERIVA BIOLOGICS, INC., 9605, MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE | /s/ Steven A. Shallcross | 06 Jan 2026 | 0001263501 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TOVX | Stock Options (right to buy) | Award | $0 | +475,000 | $0.000000 | 475,000 | 05 Jan 2026 | Common Stock | 475,000 | $0.2410 | Direct | F1 |
| Id | Content |
|---|---|
| F1 | These stock options vest pro rata on a monthly basis over 36 months. |